Sage Journals: Discover world-class research

Abstract

Primary effusion lymphoma (PEL) is an aggressive neoplasm often diagnosed in immunosuppressed patients demonstrating peritoneal, pleural, or pericardial effusions. This high-grade lymphoma is strongly associated with human herpesvirus 8 (HHV8) infection and most of the lesions also show the presence of Epstein–Barr virus in tumor cells, which lacks CD20 expression and reveals a plasmablastic morphology and phenotype. The extracavitary or solid variant of PEL is even rarer and usually affects the lymph nodes and is currently considered a clinical manifestation of the classic PEL. In the oral cavity, extracavitary PEL is extremely rare and only a few patients have been previously reported, with no detailed clinicopathological description. The recognition of oral extracavitary PEL is even more important given the occurrence of plasmablastic lymphoma in the oral mucosa, which shares many clinical, microscopic, and phenotypic features with PEL, therefore, demanding from pathologists the search for HHV8, especially in immunosuppressed patients, and an appropriate clinical evaluation. In this report, we aim to describe a very rare extracavitary PEL affecting the palate of a 36-year-old patient and to review the literature regarding the extracavitary presentation of this aggressive lymphoma. This report demonstrates the importance of searching for HHV8 infection in oral lymphomas with plasmablastic features.

Keywords

lymphoma primary effusion lymphoma plasmablastic lymphoma HHV8 EBV oral cavity

Introduction

Primary effusion lymphoma (PEL) is a high-grade neoplasm usually diagnosed in immunosuppressed patients that characteristically affects the body cavity manifesting as pleural, peritoneal, or pericardial lymphomatous effusions.¹ It was originally described in 1989 during the acquired immunodeficiency syndrome (AIDS) epidemic outburst and recognized by the World Health Organization in its third edition published in 2001.^2–5 It accounts for approximately 4% to 8.5% of all AIDS-related lymphomas, and for only 0.3% of aggressive lymphomas in human immunodeficiency virus (HIV)-negative patients.^4,6,7 In 1995 Cesarman et al⁸ demonstrated the occurrence of human herpesvirus 8 (HHV8)/Kaposi's sarcoma herpesvirus deoxyribonucleic acid (DNA) sequence within the tumor cells and the presence of this virus in now considered mandatory for establishing PEL diagnosis. Moreover, Epstein–Barr virus (EBV) is also observed in the majority of the cases and it is believed to play some role in the pathogenesis of this lymphoma subtype.⁹

It was later recognized by Chadburn et al¹¹ that PEL may manifest as solid masses out of body cavities in a varied proportion of the patients,¹⁰ and the occurrence of this extracavitary presentation may follow or precede the occurrence of effusions, although patients exclusively showing solid tumors are well recognized. Extracavitary PEL may affect different anatomic regions and lymph nodes are the most frequently described, followed by the skin and the gastrointestinal tract.^4,9

In the oral cavity, the occurrence of an extracavitary PEL represents an even more challenge in diagnosis because of its strong morphological and immunophenotypic resemblance with plasmablastic lymphomas that usually affect this location in immunosuppressed patients, since both lesions are characterized by large atypical plasmablasts, lack of B-cell markers, positivity to plasma cell proteins and association with EBV infection,¹² as originally described by Delecluse et al¹³ in 1997. Therefore, oral pathologists must be aware of this rare lymphoma subtype to be able to appropriately recognize this entity. The aim of this manuscript is to report a very rare case of extracavitary PEL affecting the oral cavity.

Case Report

This report follows the Case Report (CARE) guidelines. It refers to a 36-year-old male patient that presented a crateriform ulcerative lesion of approximately 3 cm in diameter in the palate with 5 weeks of duration. The medical history of the patient was positive for Kaposi's sarcoma in the oral cavity, which was indicative of an immunosuppressive state, although the exact reason was unknown. This tumor was originally diagnosed in 1991 based on microscopic findings only and received a descriptive diagnosis of immunoblastic sarcoma, large-cell lymphoma with immunoblastic appearance, and plasmacytic features. It was sent to the immunohistochemical laboratory of our institution some years later to comprise one of the oral pathology studies developed in this center, but no further investigation was carried out thereafter. More recently, as part of our studies with oral lymphomas, this neoplasm was retrieved and a detailed microscopic and immunohistochemical analysis was done.

A new hematoxylin and eosin-stained slide was revised and showed the presence of a lymphoid tumor in the connective tissue and an overlying stratified epithelium showing areas of acanthosis and hyperkeratosis, consistent with the palate mucosa. The neoplastic cells exhibited a diffuse growth pattern cytologically showing a plasmablastic aspect characterized by the presence of large atypical neoplastic cells with displaced nuclei and one or more prominent nucleoli. Some cells had an immunoblastic appearance with a centrally located nucleolus, while few anaplastic tumor cells exhibiting a high degree of pleomorphism were also found. Tingible body macrophages phagocytizing apoptotic bodies/debris were present and gave rise to a starry sky pattern. Atypical mitotic figures were common and some areas of tissue necrosis could also be observed (Figure 1). The main diagnostic hypotheses included a diffuse large B-cell lymphoma, a plasmablastic lymphoma, and an anaplastic large-cell lymphoma, which should have been confirmed with additional laboratorial reactions.

Figure 1.

Microscopic features of extracavitary PEL. (A) Diffuse proliferation of neoplastic cells in the connective tissue of the hard palate mucosa. Observe the overlying epithelium of the oral mucosa (H&E: 100×). (B) Tumor cells were diffusely distributed with the presence of tingible body macrophages that led to the so-called starry sky pattern (H&E; 100×). (C) Atypical plasmablasts predominated in the sample (H&E; 200×), but (D) pleomorphic cells and immunoblasts were also found (H&E; 200×). Abbreviations: PEL, primary effusion lymphoma; H&E, hematoxylin and eosin.

A large panel of immunoreactions was done to characterize the tumor cells and we observed a focal staining for leucocyte common antigen and a strong staining for CD30, as well as a diffuse and strong reaction to CD138, MUM1, and epithelial membrane antigen, and a focal staining for plasma cell (VS38c) (Figure 2). Mature B cell markers like CD20 and CD79a were negative, with a strong aberrant expression of CD3. Other reactions against CD10, BCL2, and CD56 were negative, while CD43 was focally and weakly positive. Light chain monoclonality was observed for lambda protein. Proliferative index measured by Ki67 expression achieved approximately 70%. Given the patient's previous diagnosis of Kaposi's sarcoma, CD34 reaction was done, but only normal blood vessels showed reactivity and together with the lack of a spindle cell morphology, excluded the presence of a Kaposi's sarcoma together with the lymphoid neoplasm.

Figure 2.

Immunohistochemical findings of the current extracavitary primary effusion lymphoma (PEL) showing the plasma cell phenotype of the neoplasm. (A) A strong and diffuse membrane expression of CD138 (DAB; 200×) and (B) a strong nuclear expression of MUM1 (DAB; 100×). (C) Tumor cells were negative for Kappa light chain (DAB; 100×) and (D) positive for lambda light chain (DAB; 100×).

This plasma cell immunophenotype associated with the plasmablastic morphology of the tumor cells, in an immunosuppressed patient, led to a provisional diagnosis of plasmablastic lymphoma, but reactions to identify EBV and HHV8 viruses were recommended. The immunoreaction to HHV8 using latency-associated nuclear antigen-1 clone was strongly and diffusely positive, while in situ hybridization for EBV (EBV-encoded small RNAs) also showed strong and diffuse positivity in the nuclei of tumor cells (Figure 3). Fluorescence in situ hybridization reactions using break-apart probes to investigate the mutational statuses of BCL2, BCL6, and MYC genes were negative for all of them. Therefore, a final diagnosis of an extracavitary PEL in the palate was done since the occurrence of cavitary effusions is not necessary to determine the diagnosis of the solid variant of this lymphoma. Unfortunately, we do not have information regarding the treatment and the follow-up of this patient.

Figure 3.

Presence of HHV8 and EBV in the extracavitary PEL. (A) Tumor cells were diffusely positive for EBV (EBER; 200×). (B) The presence of HHV8 was demonstrated in this neoplasm by immunohistochemistry (LANA-1) (DAB; 100×). Abbreviations: PEL, primary effusion lymphoma; HHV8, human herpesvirus 8; EBV, Epstein–Barr virus; LANA-1, latency-associated nuclear antigen-1; EBER, EBV-encoded small RNAs.

This study was approved by the local Ethical Committee and all procedures followed the ethical standards of the Helsinki Declaration of 1975, as revised in 2008.

Discussion

PEL is a very uncommon lymphoma that characteristically manifests as a body cavity effusion in immunosuppressed patients, more often males with a median age ranging from 45 to 60 years old, but that may also present as an extracavitary disease.^1,4,6,14 Following a detailed review since the publication of the fourth edition of the World Health Organization guidelines in 2008,¹⁵ we were able to identify 83 patients reported with clinicopathological data available for each case (Table 1). Some series investigating PEL showed that extracavitary manifestation comprises from 20% to 50% of the affected individuals.^6,10,14,16

Table 1.

Solid/Extracavitary Primary Effusion Lymphoma Previously Described in Literature (From 2008 to 2022).

Authors/year	Sex/age	Site	Cavitary effusion	EBV/HHV8	Immunodef./KS	Treatment	Follow-up	Outcome
Calvani et al, 2022 ⁷	M/56	LN	No	+/+	HIV/No	CDE	NS	Alive
	M/47	LN, digestive tract	No	+/+	HIV/No	CDE/ASCT	NS	Alive
	M/30	LN, ENT, bone marrow	No	+/+	HIV/Yes	CHOP-MTX	NS	Dead
	M/56	LN	No	+/+	HIV/No	CDE-MTX	NS	Alive
	M/65	LN	No	+/+	HIV/No	CHOP-MTX	NS	Alive
	M/40	LN	No	+/+	HIV/No	CHVP/ASCT	NS	Dead
	M/41	LN, skin, digestive tract	No	+/+	HIV/No	CHOP/ASCT	NS	Dead
	M/71	LN, adrenal glands	No	+/+	HIV/Yes	R-CHOEP	NS	Alive
	M/45	LN, spleen	No	+/+	HIV/Yes	CHOP-MTX	NS	Dead
	M/66	LN	No	+/+	HIV/No	CDE	NS	Alive
	M/36	LN	No	−/+	HIV/No	CDE-MTX	NS	Dead
	M/48	Testicular cord	No	−/+	HIV/Yes	CHOP-MTX	NS	Dead
	M/36	LN	No	−/+	HIV/No	ACVBP	NS	Alive
Ghosh et al, 2022 ¹⁷	M/31	Jugulodigastric skeletal muscle	No	+/+	HIV/NS	ART	22	Alive
Gu et al, 2021 ¹⁸	M/41	Bone marrow	No	+/+	HIV/NS	Chemotherapy	<1	Dead
Hentrich et al,^a 2021¹⁴	NS	Myocardium, jejunum	NS	+/+	HIV/NS	CHOP	∼22	Dead
	NS	LN, stomach, duodenum	NS	+/+	HIV/NS	CHP	∼11	Dead
	NS	Sternocleidomastoid muscle, cutaneous, thoracic wall	NS	+/+	HIV/NS	CHOEP	∼13	Dead
	NS	LN, lung	NS	−/+	HIV/NS	CHOP/DA-EPOCH	∼3	Dead
	NS	LN, kidney	NS	+/+	HIV/NS	CHOEP	12	Dead
Bruce-Brand et al, 2020 ¹⁹	F/32	Skin/intravascular	NS	+/+	HIV/Yes	NS	< 1	Dead
Ahmed et al, 2020 ²⁰	M/59	Skin/rectal	No	−/+	HIV/Yes	ART/R-CHOP	72	Alive
Krishnamurthy et al, 2020 ²¹	M/54	Thalamus	No	+/+	HIV/NS	Rituximab/MTX/Radiation	NS	NS
Tong et al, 2020 ²²	M/76	Bladder/ureter	Pleural	+/+	No/No	CHOP/ brentuximab vedotin/ bendamustine	>3	Dead
Saggini et al, 2020 ²³	M/42	Skin	No	−/+	HIV/NS	ART	18	Alive
Zanelli et al, 2019 ²⁴	M/42	Gastric and duodenal	No	+/+	Small bowel transplantation/NS	None	1	Dead
Kastnerova et al, 2020 ²⁵	M/67	Skin	No	+/+	long-term corticosteroid therapy/Yes	None	<1	Dead
Campogiani et al, 2019 ²⁶	M/42	Subcutaneous	No	−/+	HIV/NS	ART/ganciclovir	19	Alive
Sandoval-Sus et al, 2019 ²⁷	M/50	Superior chest wall	No	−/+	HIV/NS	ART/steroids/radiation/ brentuximab vedotin	16	Alive
Cain et al, 2018 ²⁸	M/29	Multiple organs/intravascular	Pleural	+/+	HIV + Renal transplantation /Yes	ART	< 1	Dead
Chen et al, 2018 ²⁹	M/51	Skin and tonsils	No	−/+	HIV + HEV/Yes	Liposomal doxorubicin/CHOP	54	Alive
Nabergoj et al, 2019 ³⁰	M/44	Bilateral adrenal gland	No	+/+	HIV/NS	DA-EPOCH/DHAP/cyclophosphamide	24	Alive
Hashmi et al, 2018 ³¹	M/51	LN	No	+/+	HIV/No	ART/EPOCH	<1	Dead
Oster et al, 2018 ³²	M/49	GI tract	No	−/+	HIV/No	CHOP/lenalidomide	12	Alive
Périer et al, 2017 ³³	M/44	LN/visceral involvement	NS	NS/+	Rituximab-associated immunodepression/NS	CHOP-MTX	20	Alive
Nam et al, 2017 ³⁴	M/41	LN	No	+/+	HIV + HCV/NS	ART	NS	NS
Fung et al, 2017 ³⁵	M/26	Subcutaneous (Thigh + Gluteal)	Yes	+/+	HIV/Yes	Ifosfamide, Carboplatin and Etoposide/DHAP	6	Dead
Ibrahim et al, 2017 ³⁶	M/21	Pelvic, iliac, pubic and sacrum bones and bone marrow	NS	+/+	No/No	DA-EPOCH/methotrexate	8	Alive
Epperla et al, 2016 ³⁷	M/44	Maxillary sinus, bladder and bone marrow	No	+/+	HIV + HBV/Yes	ART/Dexamethasone/Cytarabine/ R-EPOCH	NS	Alive
Sampath et al, 2015 ³⁸	M/38	Jejunal region	No	+/+	HIV/NS	NS	NS	NS
Liao et al, 2015 ³⁹	M/48	GI tract	Abdominal	−/+	HIV/Yes	NS	NS	NS
Katz et al, 2015 ⁴⁰	M/46	Paracardial region	Pleural	+/+	HIV/NS	ART/CHOP	NS	Alive
Crane et al, 2014 ⁴¹	M/53	Intravascular and skin	Pleural	+/+	HIV/No	ART	∼1	Dead
Juskevicius et al, 2014 ⁴²	M/51	LN	Abdominal	+/+	HIV/NS	Prednisone/R-CHOP/ACVBP/AHSCT	32	Alive
Juskevicius et al, 2014 ⁴²	M/63	LN	No	+/+	HIV/NS	R-CHOP	50	Alive
Shah et al, 2014 ⁴³	M/33	GI tract (colonic region)	No	+/+	HIV/NS	ART/dexamethasone/R-EPOCH/methotrexate/cytarabine	6	Alive
Pielasinski et al, 2014 ⁴⁴	M/33	Skin	No	+/+	HIV/No	ART/CHOP/methotrexate, prednisone and cytarabine	20	Alive
Crane et al, 2014 ⁴⁵	M/59	Subcutaneous fat (intravascular)	No	+/+	HIV/NS		2	Dead
Courville et al, 2014 ⁴⁶	M/60	Retroperitoneal	NS	−/+	HIV/NS	NS	NS	NS
	M/55	LN	NS	+/+	NS/NS	NS	NS	NS
	F/29	Spleen, LN, pelvis	NS	+/+	No/NS	NS	NS	NS
	M/44	Skin	NS	+/+	HIV/NS	NS	NS	NS
	M/61	LN	NS	+/+	No/NS	R-CHOP	55	Alive
	M/47	Left ventricular endocardium	NS	−/+	HIV/NS	R-CHOP/ methotrexate /cytarabine EPOCH/high-dose methotrexate	40	Alive
	M/44	LN	NS	+/+	HIV/NS	NS	NS	NS
	M/44	LN	NS	+/+	HIV/NS	Chemotherapy	204	Alive
Henao-Martínez et al, 2013 ⁴⁷	M/45	Intracardiac	No	+/+	HIV/Yes	Tenofovir, emtricitabine and ritonavir-boosted atazanavir/DA- EPOCH	12	Alive
Marak et al, 2013* ⁴⁸	M/35	Cardiac (atrial)	Pleural/Pericardial	−/+	HIV/NS	ART/R-EPOCH	< 1	Alive
Pan et al, 2012 ⁴⁹	M/26	LN	No	+/+	HIV/NS	NS	6	Alive
	M/37	LN/colon	No	+/+	HIV/NS	NS	< 1	Dead
	M/39	Stomach	No	−/+	HIV/NS	NS	NS	NS
	M/77	LN	No	+/+	HIV/NS	NS	33	Alive
	M/39	Skin	No	+/+	HIV/NS	NS	NS	NS
	M/45	Cardiac	No	+/+	HIV/NS	NS	NS	NS
	M/48	Stomach	No	+/+	HIV/NS	NS	NS	NS
	M/41	LN	No	+/+	HIV/NS	NS	NS	NS
	M/46	Pelvis	No	+/+	HIV/NS	NS	15	Alive
Arora et al, 2012 ⁵⁰	M/46	LN/pelvis	NS	+/+	HIV/NS	NS	NS	NS
Kim et al, 2012 ⁵¹	M/55	Colon/ileum	NS	−/+	HIV/NS	NS	13	Alive
	M/42	LN	NS	+/+	HIV/NS	NS	25	Alive
	M/42	LN	NS	−/+	HIV/NS	NS	NS	NS
El-Ayass et al, 2012 ⁵²	M/48	Colon	No	NS/+	HIV/NS	ART/EPOCH	14	Alive
Li et al, 2012 ⁵³	M/31	Skin	No	+/+	HIV/NS	Cytoreduction therapy (Leukeran and Dorison)/CHOP	< 2	Alive
Giessen et al, 2012 ⁵⁴	M/38	LN	No	+/+	HIV/NS	ART/CHOP	NS	Alive
Andrews et al, 2011 ⁵⁵	M/46	CNS/cardiac	No	−/+	HIV/Yes	ART/R-CHOP/methotrexate, cytarabine, and hydrocortisone /EPOCH	NS	NS
Testa et al, 2010^b ⁵⁶	M/55	Multiple organs	No	−/+	Liver transplantation/NS	No	Post-morten	Dead
Valera et al, 2010** ⁵⁷	M/NS	Paravertebral mass	No	NS/+	HIV/NS	NS	36	Alive
	M/NS	LN	No	NS/+	HIV/NS	NS	2	Dead
	M/NS	LN	No	NS/+	HIV/NS	NS	NS	NS
Mani et al, 2010 ⁵⁸	M/37	Gall bladder	No	+/+	HIV/NS	NS	NS	NS
Zhang et al, 2010 ⁵⁹	M/46	LN	No	+/+	HIV/Yes	ART/high-dose steroid, rituximab and cyclophosphamide	< 1	Dead
Ferry et al, 2009*** ⁶⁰	M/59	Multiple organs/intravascular	No	−/+	HIV/NS	ART	< 1	Dead
Mylona et al, 2008 ⁶¹	M/39	LN/lung	No	NS/+	HIV/Yes	ART/dose-adjusted etoposide, vincristine, cyclophosphamide/ESHAP	24	Dead

* This tumor was CD20 positive and CD138 negative. **Valera et al (2010) did not provide all clinicopathological data individually detailed for each patient. Regarding EBER the authors informed that 2 out of their 3 patients were positive and their age ranged from 49 to 62 years-old. Simultaneous occurrence of Kaposi's sarcoma was not described neither treatment employed. *** Ferry et al (2009) reported their Case 2 as “HHV8-positive intravascular large B-cell lymphoma,” but their description is currently consistent with an extracavitary PEL. Abbreviations: LN, lymph node; NS, not specified; ENT, ear, nose, and throat; KS, Kaposi's sarcoma; CNS, central nervous system; CDE, cyclophosphamide, doxorubicin, etoposide; ASCT, autologous stem cell transplant; ART, antiretroviral therapy; ESHAP, dose-adjusted etoposide, cisplatin, cytarabine, methylprednisolone; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin; R-EPOCH, rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin; DA-EPOCH, dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin; CHVP, cyclophosphamide, adriamycin, etoposide, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOEP, rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; ACVBP, adriamycin, cyclophosphamide, vindesine, bleomycin, and prednisone; DHAP, dexamethasone, cytarabine, and cisplatin; CHP, cyclophosphamide, doxorubicin, prednisolone; HIV, human immunodeficiency virus; HHV8, human herpesvirus 8; EBV, Epstein–Barr virus; EBER, EBV-encoded small RNAs.

One of the patients did not have data available for HHV8 status and was exclude from this review.

The authors investigated EBV by immunohistochemistry and by PCR.

Despite some slight differences in the protein expression patterns,⁴⁹ the microscopic, the immunophenotype, and the association with HHV8 and EBV viruses are similar between classic PEL and extracavitary PEL, suggesting that they represent the clinical spectrum of the same entity. This assumption was later supported by genetic and proteomic studies that showed a strong similarity regarding molecular expression profile in both manifestations,^62,63 as well as survival rates.⁶

Solid PEL is more commonly diagnosed in the lymph nodes, although many other extranodal and extracavitary locations may also be affected, like the skin, the gastrointestinal tract, and other organs.⁴⁹ Some reports described an intravascular presentation of the disease, which must be differentiated from intravascular large B-cell lymphoma.⁴¹ Moreover, disseminated solid PEL has also been described affecting 2 or more sites simultaneously,³² and postmortem reports are also available in literature.⁵⁶ In the oral cavity, extracavitary PEL is extremely rare and very poorly documented. Hu et al¹⁶ in their series of 70 PEL included 2 tumors affecting the skin/buccal region and Mate et al¹² described a solid PEL affecting the tongue of a 42-year-old HIV-positive male patient who died 2 weeks after treatment initiation. In 1997 Buske et al⁶⁴ described a patient diagnosed as anaplastic large cell lymphoma of the B-cell type positive for HHV8 and EBV (Latent membrane protein 1—LMP1) that affected the hard palate and other sites, while Carbone et al⁶² included 2 patients affecting the Waldeyer's ring in their series of 4 PEL, both died after a short follow-up, and Boulanger et al⁶⁵ included 1 patient affected by a maxillary sinus in their series of 28 PEL.

Other lymphomas manifesting as cavitary effusions must be distinguished from classic PEL,⁶⁶ while the list of differential diagnoses for the solid variant is also complex. Lymphomas characterized by a plasmablastic differentiation represent the most important entities to be distinguished from extracavitary PEL (Table 2). Plasmablastic lymphoma more frequently affects the oral mucosa⁶⁷ and was the main differential diagnosis in the present case; however, it does not present HHV8 positivity. Similarly, anaplastic lymphoma kinase (ALK)+ large B-cell lymphoma is also negative for HHV8 and EBV, while anaplastic variant of plasmacytoma/multiple myeloma lacks an association with HHV8, and EBV is only rarely found.^16,68 Although diffuse large B cell lymphoma not otherwise specified represents the most common lymphoma subtype in the oral cavity⁶⁹ and must be considered in the differential diagnosis, it strongly expresses CD20 protein and other mature B cell markers. Anaplastic large-cell lymphoma may be an important mimicker of PEL³⁴ and both demonstrate CD30 expression, and this differentiation can be even more difficult due to the frequent aberrant expression of T-cell markers in PEL^7,16,70 as demonstrated in our patient, and although these neoplasms usually have polyclonal T-cell populations, a few tumors were shown to have clonal T-cells demonstrated by DNA analysis.⁷¹ Courville et al⁴⁶ showed in their series of 8 extracavitary PEL that aberrantly expressed T-cell markers include CD3, CD43, CD7, CD45RO, and cytotoxic granules. The expression of plasmacytic markers and the presence of HHV8 and EBV are very useful to achieve the correct diagnosis.

Table 2.

Important Differential Diagnoses for Extracavitary Primary Effusion Lymphoma.

Lesion	Sex	Age	Site	Immunosuppression	IHC^a	HHV8	EBV	Genetics^b	Prognosis
Extracavitary PEL	M	Young and middle-aged adults	LN	Frequent	ALK-, CD20-, PAX5-, CD79a+/-, EMA+, CD138+, VS38c+, MUM1+, Ki67 80%-90%	Positive	Positive (50−80%)	Monoclonal proliferation of tumor cells; immunoglobulin heavy-chain genes are rearranged; Lack of MYC, BCL2, BCL6, ALK rearrangements.	Poor
Plasmablastic lymphoma	M	8-62 (41 years)	Oral cavity and GIT	Frequent	ALK-, CD20-, PAX5-, CD79a+/-, EMA+, CD138+, VS38c+, MUM1+, Ki67 80%-90%	Negative	Positive (60−75%)	MYC translocation in 50% of the cases.	Poor
ALK + LBCL	M	9-72 (43 years)	LN	Rare	ALK+, CD20-, PAX5-, CD79a-, EMA+, CD138+, VS38c+, MUM1+, Ki67 80%-90%	Negative	Negative	ALK translocation.	Poor
Anaplastic multiple myeloma	M	> 50 years	Bone	Rare	ALK-, CD20-, PAX5-, CD79a-, EMA+, CD138+, VS38c+, MUM1+, CD56+/-, Cyclin D1 +/-, Ki67 80%-90%	Negative	Rare	Hyperdiploid; NonHyperdiploid (CCND1, CCND2, CCND3, NSD2, MAF, MYC translocations) ; Others (mutations in TP53, FGFR3, CDKN2C, RB1, etc).	Variable^c
DLBCL NOS	M	50-70 years	LN	Variable	ALK-, CD20+, PAX5+, CD79a+, EMA-, CD138-, VS38c-, MUM1+/-, CD10+/-, Bcl6+/-, Cyclin D1-, Ki67 40%-70%	Negative	Negative^d	Translocations in MYC or BCL2 or BCL6^e.	Variable^c
ALK + ALCL	M	< 30 years	LN	Rare	CD30+, ALK+, CD20-, PAX5-, CD79a-, EMA+, CD138-, VS38c-, MUM1-, CD45RO+, CD3-, Cytotoxic granules+, Ki67 50%-70%	Negative	Negative	ALK translocation with different gene partners	Variable^c Better than ALK- ALCL
ALK-ALCL	M	40-60 years	LN	Rare	CD30+, ALK-, CD20-, PAX5-, CD79a-, EMA+, CD138-, VS38c-, MUM1-, CD45RO+, CD3-, Cytotoxic granules+, Ki67 50%-70%	Negative	Negative	DUSP22, STAT3, JAK1 and TP63 mutations	Variable^c Worse than ALK + ALCL
MCD	M	Adults	LN	Variable, depending on subtype	ALK-, CD20+/-, PAX5-, CD79a+/-, EMA+, CD138-, VS38c+, MUM1+, Ki67 20%-40%	Variable	Negative	Polyclonal/oligoclonal proliferations	Variable^c
HHV8+ DLBCL NOS	M	Adults	LN	Frequent	ALK-, CD20+, CD79a-, MUM1+, CD138-, Cyclin D1-, Ki67 40%-70%	Positive	Negative	Poorly understood; Lack of immunoglobulin somatic hypermutations.	Poor
HHV8 + germinotropic lymphoproliferative disorder	M	27-86 (58.6 years)	LN	Rare	ALK-, CD20-, CD79a-, CD138-, VS38c+, MUM1+, Ki67 80%-90%	Positive	Positive	Polyclonal or oligoclonal proliferations	Favorable

IHC: immunohistochemistry; PEL: primary effusion lymphoma; M: male; yrs: years; LN: Lymph node; GIT: gastrointestinal tract; ALK: anaplastic lymphoma kinase; DLBCL NOS: diffuse large B-cell lymphoma not otherwise specified; ALCL: anaplastic large cell lymphoma; MCD: multicentric castleman disease; HIV, human immunodeficiency virus; HHV8, human herpesvirus 8; EBV, Epstein–Barr virus; EMA, epithelial membrane antigen; +: positive; −: negative; +/-: Variable.

These are the most frequently used markers for the diagnosis of these lesions.

These are the most frequently reported genetic events in these lesions, but other less common mutations have already been described.

The prognosis of patients affected by these lesions will depend on different important prognostic factors. e. In the presence of EBV the tumor is classified as EBV + DLBCL NOS and represents less than 5% of all DLBCL NOS cases.

In the presence of MYC and BCL2, MYC and BCL6, MYC and BCL2 and BCL6 translocations the diagnosis is high-grade B-cell lymphoma.

It is known that HHV8 may be found in other lymphomas and lymphoproliferative disorders, which should be differentiated from extracavitary PEL. Multicentric castleman disease is a clinicopathological entity that encompasses a group of systemic polyclonal lymphoproliferative disorders in which there is a proliferation of morphologically benign lymphocytes, plasma cells, and vessels.⁷⁰ It is associated with HHV8, but lacks EBV infection, and its microscopic features characterized by follicles showing the so-called “onion skinning” or widened concentric rings of mantle zone lymphocytes, and prominent penetrating venules are usually very suggestive of the diagnosis. Another important differential diagnosis is HHV8 + diffuse large B-cell lymphoma that usually arises in patients with clinical features of HHV8 + multicentric Castleman disease in individuals showing a profound immunodeficiency, but these tumors express CD20 and lack CD138 protein and EBV infection.¹⁶ More recently, it was recommended that in the absence of EBV infection and with cytoplasmic IgM, lambda, and/or associated with multicentric Castleman disease, extracavitary PEL would be better diagnosed as HHV8 + large B-cell lymphoma.⁷²

Finally, HHV8 + germinotropic lymphoproliferative disorder must also be ruled-out when lymph nodes are affected and this lesion may also show EBV positivity. It usually occurs in HIV-negative patients that show effacement of the germinal centers by plasmablasts in the affected lymph node, but different from PEL it does not express CD138 and often shows an indolent clinical course.^70,73 Despite the differences between PEL and these HHV8-positive disorders, they have overlapped histological and clinical features and their distinction may be very difficult in some cases.^5,74 The genetic basis of these lesions remains poorly understood and characterized; however, PEL has been shown to lack MYC, BCL2, and BCL6 genes translocation, as shown in our patient, but with hypermutated genes and immunoglobulin gene rearrangements, while multicentric Castleman disease and HHV8 + germinotropic lymphoproliferative disorder cells were shown to have a polyclonal/oligoclonal nature, and HHV8 + diffuse large B-cell lymphoma has no immunoglobulin somatic hypermutations.⁷¹

In the present patient, due to its retrospective nature and because it represents a specimen received at the beginning of the 1990s, it is not possible to determine the occurrence of any cavitary effusion; however, such occurrence is not necessary to confirm the diagnosis of an extracavitary PEL since the development of a solid manifestation of this lymphoma may occur before, later or may even represent the only manifestation of the disease.^10,16 Moreover, given the occurrence of an oral Kaposi's sarcoma in our patient, it is very likely that he was immunosuppressed, although it was also not possible to determine if the patient was HIV positive. The simultaneous occurrence of Kaposi's sarcoma and extracavitary PEL was previously demonstrated,^6,16 but in our patient, the microscopic exam of the lymphoma did not show evidence of a simultaneous Kaposi's sarcoma, with the absence of spindle-cell proliferations and CD34 expression. Meanwhile, it is important to consider that classic and extracavitary PEL may also develop under other immunosuppressive conditions, like in transplanted patients and in elderly patients.²⁴

There are currently no standardized therapeutic schemes used to treat patients affected by classic or extracavitary PEL. HIV-related immunosuppression must include antiretroviral therapy, while different chemotherapeutic schemes have been applied, more often cyclophosphamide, hydroxydaunorubicin (also called doxorubicin or adriamycin), vincristine (Oncovin) and prednisolone combined or not with Rituximab, despite the lack of CD20 expression by tumor cells. Additional regimens like etoposide, prednisolone, oncovin, cyclophosphamide, and hydroxydaunorubicin (EPOCH), dose-adjusted EPOCH (DA-EPOCH), dexamethasone, high-dose arabinoside-C (cytarabine) and platinol (cisplatin), the use of methotrexate and brentuximab vedotin, among others have also been reported. The prognosis of the patients is very poor with median survival ranging from 10.2 to 22 months and a 2-years survival rate ranging from 15.4% to 71.5%.^{4,6,7,9,14,75} Interestingly, few individuals present a satisfactory recovery after treatment initiation and the search for new clinical and molecular prognostic parameters is highly desirable. Currently, the number of cavities involved, the type of cavity affected, the immunologic state, the presence of EBV, and elevated interleukin-6 may represent potential prognostic variables for these patients.^75,76

In conclusion, extracavitary PEL is a very rare disease and its manifestation in the oral cavity is even more uncommon, demanding from pathologists a careful evaluation of lymphomas characterized by plasmablastic morphology that is more often diagnosed in this site like plasmablastic lymphoma. In these circumstances, the search for HHV8 is recommended and a careful systemic evaluation of the patient is also advisable to investigate the occurrence of possible cavitary effusions, especially in immunosuppressed patients.

Footnotes

Acknowledgments

The authors acknowledge the inputs of Dr Roman Carlos (in memorian) to the study of this case.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical Approval

This study was approved by the local Ethical Committee of the Piracicaba Dental School of the University of Campinas and all procedures followed the ethical standards of the Helsinki Declaration of 1975, as revised in 2008.

Funding

The authors received the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), the São Paulo State Research Foundation (FAPESP), the Coordination for the Improvement of Higher Education Personnel (CAPES) (Financial code 001) and the National Council for Scientific and Technological Development (CNPq).

ORCID iD

Felipe P. Fonseca

References

Carbone

Gloghini

KSHV/HHV8-associated lymphomas. Br J Haematol. 2007;140(1):13‐24.

Knowles

Inghirami

Ubriaco

Dalla-Favera

Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood. 1989;73(3):792‐799.

Jaffe

Harris

Stein

Vardiman

JW.

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. IARC; 2001.

Okada

Goto

Yotsumoto

Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res. 2014;3(3):65‐74.

Vega

Miranda

Medeiros

LJ.

KSHV/HHV8-positive large B-cell lymphomas and associated diseases: A heterogeneous group of lymphoproliferative processes with significant clinicopathological overlap. Mod Pathol. 2020;33(1):18‐28.

Guillet

Gérard

Meignin

, et al. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. Am J Hematol. 2016;91(2):233‐237.

Calvani

Gérard

Fadlallah

, et al. A comprehensive clinicopathologic and molecular study of 19 primary effusion lymphomas in HIV-infected patients. Am J Surg Pathol. 2022;46(3):353‐362.

Cesarman

Chang

Moore

Said

Knowles

DM.

Kaposi’s sarcoma—associated herpesvirus-like DNA sequences in AIDS-related body-cavity–based lymphomas. N Engl J Med. 1995;332(18):1186‐1191.

Gathers

Galloway

Kelemen

Rosenthal

Gibson

Munoz

Primary effusion lymphoma: A clinicopathologic perspective. Cancers (Basel). 2022;14(3):722.

10.

Aguilar

Laberiano

Beltran

Diaz

Taype-Rondan

Castillo

JJ.

Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. Leuk Lymphoma. 2020;61(9):2093‐2102.

11.

Chadburn

Hyjek

Mathew

Cesarman

Said

Knowles

DM.

KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28(11):1401‐1416.

12.

Mate

Navarro

Ariza

, et al. Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphoma. Hum Pathol. 2004;35:632‐635.

13.

Delecluse

Anagnostopoulos

Dallenbach

, et al. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413‐1420.

14.

Hentrich

Müller

Wyen

, et al. Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. Br J Haematol. 2021;194(3):642‐646.

15.

Swerdlow

Campo

Harris

, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC; 2008.

16.

Pan

Chen

, et al. Primary effusion lymphoma: A clinicopathological study of 70 cases. Cancers (Basel). 2021;13(4):878.

17.

Ghosh

Zvavanjanja

Baalwa

An unusual presentation of extracavitary primary effusion lymphoma: Internal jugular vein occlusion, intractable symptoms of intracranial hypertension, and prolonged remission after highly active antiretroviral therapy. Case Rep Hematol. 2022;2022(1):6046783.

18.

Pan

ML.

Thinking outside the cavity: Effusion lymphoma primary to bone marrow. Clin Case Rep. 2021;9(5):e04100.

19.

Bruce-Brand

Rigby

Kaposi sarcoma with intravascular primary effusion lymphoma in the skin: A potential pitfall in HHV8 immunohistochemistry interpretation. Int J Surg Pathol. 2020;28(8):868‐871.

20.

Ahmed

Poliquin

Julien

Routy

JP.

Extracavitary primary effusion lymphoma recurring with syphilis in an HIV-infected patient. BMJ Case Rep. 2020;13(11):e235204.

21.

Krishnamurthy

Sriganeshan

Extracavitary primary effusion lymphoma presenting as a thalamic mass in a patient with multicentric castleman disease. Blood. 2020;135(14):1190.

22.

Tong

Jadallah

Rodgers

Jung

Fulman

Swaika

A rare case of extracavitary primary effusion lymphoma in the bladder and ureter. Case Rep Hematol. 2020;2020(1):6124325.

23.

Saggini

Di Prete

Facchetti

Rapisarda

Anemona

Panniculitis-like presentation of extracavitary primary effusion lymphoma. Am J Dermatopathol. 2020;42(6):446‐451.

24.

Zanelli

Bertuzzi

Zizzo

Martino

Sabattini

Ascani

Extracavitary primary effusion lymphoma in a post-transplantation patient. Br J Haematol. 2019;187(5):555.

25.

Kastnerova

Belousova

Michal

Ptakova

Michal

Kazakov

DV.

Kaposi sarcoma in association with an extracavitary primary effusion lymphoma showing unusual intravascular involvement: Report of a case harboring a FAM175A germline mutation. Am J Dermatopathol. 2020;42(1):55‐60.

26.

Campogiani

Cerva

Maffongelli

, et al. Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir. AIDS Res Ther. 2019;16(1):15.

27.

Sandoval-Sus

Brahim

Khan

, et al. Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma. Int J Hematol. 2019;109(5):622‐626.

28.

Cain

Yoong

Lipkin

, et al. Rapidly progressive intravascular primary effusion lymphoma in an HIV-positive renal transplant recipient. Histopathology. 2018;72(2):339‐341.

29.

Chen

Mehraj

Szabo

Routy

Michel

Routy

JP.

Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV. Curr Oncol. 2018;25(6):e592‐e596.

30.

Nabergoj

Tshikung

Tsopra

Ghinescu

Samii

Calmy

Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient. Ann Hematol. 2019;98(5):1317‐1318.

31.

Hashmi

Murray

Al-Quran

Tse

Primary effusion lymphoma without an effusion: A rare case of solid extracavitary variant of primary effusion lymphoma in an HIV-positive patient. Case Rep Hematol. 2018;2018(1):9368451.

32.

Oster

Stein

Kitahara

Alkan

Huang

Kaposi sarcoma–associated herpesvirus/human herpesvirus 8–associated extracavitary primary effusion lymphoma presenting as multiple lymphomatous polyposis. Human Pathol. 2018;79(1):177‐183.

33.

Périer

Savey

Marcelin

, et al. De novo human herpesvirus 8 tumors induced by rituximab in autoimmune or inflammatory systemic diseases. Arthritis Rheumatol. 2017;69(11):2241‐2246.

34.

Nam

Tam

An intrasinusoidal extracavitary variant of primary effusion lymphoma. Blood. 2017;130(6):836.

35.

Fung

Raghupathy

Chan

, et al. HHV8 Genotype study in an HIV+ patient with concurrent kaposi sarcoma and extracavitary primary effusion lymphoma. J Clin Pathol. 2017;70(9):814‐816.

36.

Ibrahim

Saqib

Mohammad

Ding

Hussein

Atallah

JP.

KSHV-associated extracavitary primary effusion lymphoma in an HIV seronegative patient: A case report and review of the literature. Postgrad Med. 2017;129(3):402‐407.

37.

Epperla

Harrington

Hemauer

Shah

NN.

Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. Am J Hematol. 2016;91(11):1161‐1164.

38.

Sampath

Manipadam

Nair

Samarasam

Extracavitary primary effusion lymphoma: A case report from India. Indian J Pathol Microbiol. 2015;58(4):496‐499.

39.

Liao

Cai

Yue

Qing

Extracavitary/solid variant of primary effusion lymphoma presenting as a gastric mass. Exp Mol Pathol. 2015;99(3):445‐448.

40.

Katz

Rose

Rivera

Bray

HIV-associated primary effusion lymphoma presenting as a paracardial mass. BMJ Case Rep. 2015;2015(1): bcr2014208718.

41.

Crane

Ambinder

Shirley

, et al. HHV-8-positive and EBV-positive intravascular lymphoma: An unusual presentation of extracavitary primary effusion lymphoma. Am J Surg Pathol. 2014;38(3):426‐432.

42.

Juskevicius

Dietsche

Lorber

, et al. Extracavitary primary effusion lymphoma: Clinical, morphological, phenotypic and cytogenetic characterization using nuclei enrichment technique. Histopathology. 2014;65(5):693‐706.

43.

Shah

Harrison

Stonecypher

Frank

Amorosa

Svoboda

Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis. Clin Lymphoma Myeloma Leuk. 2014;14(5):e157‐e160.

44.

Pielasinski

Santonja

Rodríguez-Pinilla

Requena

Extracavitary primary effusion lymphoma presenting as a cutaneous tumor: A case report and literature review. J Cutan Pathol. 2014;41(9):745‐753.

45.

Crane

Xian

Burns

Borowitz

Duffield

Taube

JM.

Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma. J Cutan Pathol. 2014;41(12):928‐935.

46.

Courville

Sohani

Hasserjian

Zukerberg

Harris

Ferry

JA.

Diverse clinicopathologic features in human herpesvirus 8-associated lymphomas lead to diagnostic problems. Am J Clin Pathol. 2014;142(6):816‐829.

47.

Henao-Martínez

Gray

González-Fontal

Reves

Intracardiac extra-cavitary primary effusion lymphoma in an HIV-infected patient. Int J STD AIDS. 2013;24(1):78‐79.

48.

Marak

Ponea

Shim

Shaheen

Guddati

AK.

Extracavitary manifestation of primary effusion lymphoma as a right atrial mass. Case Rep Oncol. 2013;6(1):114‐118.

49.

Pan

Zhang

ZBJ

, et al. Extracavitary KSHV-associated large B-cell lymphoma: A distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases. Am J Surg Pathol. 2012;36(8):1129‐1140.

50.

Arora

Cossor

FI.

Diagnosis of extracavitary primary effusion lymphoma by urine cytology. Blood. 2012;119(12):2707.

51.

Kim

Leventaki

Bhaijee

Jackson

Medeiros

Vega

Extracavitary/solid variant of primary effusion lymphoma. Ann Diagn Pathol. 2012;16(6):441‐446.

52.

El-Ayass

Karcher

Aragon-Ching

JB.

Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: A case report and review of literature. Clin Lymphoma Myeloma Leuk. 2012;12(2):144‐147.

53.

Hsiao

Chen

, et al. Human herpesvirus 8-associated lymphoma mimicking cutaneous anaplastic large T-cell lymphoma in a patient with human immunodeficiency virus infection. J Cutan Pathol. 2012;39(2):274‐278.

54.

Giessen

C Di

Gioia

Huber

, et al. Primary effusion lymphoma (PEL) without effusion: A patient case report of a PEL solid variant. J Clin Pathol. 2012;65(2):189‐190.

55.

Andrews

Cho-Park

Ferry

Abramson

Robbins

GK.

Kaposi's sarcoma-associated herpesvirus-related solid lymphoma involving the heart and brain. AIDS Res Treat. 2011;2011(1):729854.

56.

Testa

Baiocchini

Comandini

, et al. Fatal sclerosing peritonitis associated with primary effusion lymphoma after liver transplantation: A case report. Transplant Proc. 2010;42(9):3849‐3853.

57.

Valera

Balagué

Colomo

, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11):1686‐1694.

58.

Mani

Climent

Colomo

Pittaluga

Raffeld

Jaffe

ES.

Gall bladder and extrahepatic bile duct lymphomas: Clinicopathological observations and biological implications. Am J Surg Pathol. 2010;34(9):1277‐1286.

59.

Zhang

Yang

Hong

Feldman

Bhattacharyya

PK.

Kaposi sarcoma-associated herpesvirus (human herpesvirus type 8)-associated extracavitary lymphoma: Report of a case in an HIV-positive patient with simultaneous kaposi sarcoma and a review of the literature. Acta Haematol. 2010;123(4):237‐241.

60.

Ferry

Sohani

Longtine

Schwartz

Harris

NL.

HHV8-positive, EBV-positive hodgkin lymphoma-like large B-cell lymphoma and HHV8-positive intravascular large B-cell lymphoma. Mod Pathol. 2009;22(5):618‐626.

61.

Mylona

Baraboutis

Georgiou

, et al. Solid variant of primary effusion lymphoma in successfully treated HIV infection: A case report. Int J STD AIDS. 2008;19(8):570‐572.

62.

Carbone

Gloghini

Vaccher

, et al. Kaposi’s sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: A tissue-based variant of primary effusion lymphoma. J Mol Diagn. 2005;7(1):17‐27.

63.

Carbone

Volpi

Caccia

, et al. Extracavitary KSHV-positive solid lymphoma: A large B-cell lymphoma within the spectrum of primary effusion lymphoma. Am J Surg Pathol. 2013;37(9):1460‐1461.

64.

Buske

Hannig

Hiddemann

Bodemer

Human herpesvirus-8 (HHV-8) DNA associated with anaplastic large cell lymphoma of the B-cell type in an HIV-1-positive patient. Int J Cancer. 1997;73(2):303‐304.

65.

Boulanger

Gerard

Gabarre

Prognostic factors and outcome of human herpesvirus 8—associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23(19):4372‐4380.

66.

Gisriel

Yuan

Braunberger

, et al. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: A distinct entity with unique clinicopathologic characteristics. Mod Pathol. 2022;35(10):1411‐1422.

67.

Fonseca

Robinson

van Heerden

WFP.

Oral plasmablastic lymphoma: A clinicopathological study of 113 cases. J Oral Pathol Med. 2021;50(6):594‐602.

68.

Zhou

Cheng

Karrs

, et al. Clinicopathologic and molecular characterization of Epstein-Barr Virus-positive plasmacytoma. Am J Surg Pathol. 2022;46(10):1364‐1379.

69.

de Arruda

JAA

Schuch

Conte Neto

, et al. Oral and oropharyngeal lymphomas: A multi-institutional collaborative study. J Oral Pathol Med. 2021;50(6):603‐612.

70.

Swerdlow

Campo

Harris

, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC; 2017.

71.

Chadburn

Said

Gratzinger

, et al. HHV8/KSHV-Positive Lymphoproliferative disorders and the Spectrum of plasmablastic and plasma cell neoplasms: 2015 SH/EAHP workshop report-part 3. Am J Clin Pathol. 2017;147(2):171‐187.

72.

Campo

Jaffe

Cook

, et al. The International Consensus Classification of mature lymphoid neoplasms: A report from the clinical advisory committee. Blood. 2022;140(11):1229‐1253.

73.

Zanelli

Zizzo

Bisagni

, et al. Germinotropic lymphoproliferative disorder: A systematic review. Ann Hematol. 2020;99(10):2243‐2253.

74.

Parente

Zanelli

Zizzo

, et al. Primary effusion lymphoma metachronous to multicentric castleman disease in an immunocompetent patient. Pathol Res Pract. 2020;216(7):153024.

75.

Lurain

Polizzotto

Aleman

, et al. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood. 2019;133(16):1753‐1761.

76.

Castillo

Shum

Lahijani

Winer

Butera

JN.

Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012;53(12):2378‐2382.

Extracavitary Primary Effusion Lymphoma Affecting the Oral Cavity: A Rare Case Report

Abstract

Keywords

Introduction

Case Report

Discussion

Footnotes

Acknowledgments

Declaration of Conflicting Interests

Ethical Approval

Funding

ORCID iD

References